Fate Therapeutics (FATE) Revenue (2012 - 2026)

Fate Therapeutics' Revenue history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Revenue fell 20.26% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 52.64% YoY) and the FY2025 annual result came in at $6.6 million, down 51.24% from the prior year.
• Revenue was $1.3 million for Q1 2026 at Fate Therapeutics, down from $1.4 million in the prior quarter.
• Across five years, Revenue topped out at $59.0 million in Q1 2023 and bottomed at $933000.0 in Q2 2023.
• A 5-year average of $10.7 million and a median of $1.9 million in 2024 frame the typical range for Revenue.
• Peak annual rise in Revenue reached 625.83% in 2024, while the deepest fall reached 96.74% in 2024.
• Fate Therapeutics' Revenue stood at $44.4 million in 2022, then sank by 96.22% to $1.7 million in 2023, then rose by 10.98% to $1.9 million in 2024, then retreated by 26.4% to $1.4 million in 2025, then slipped by 5.11% to $1.3 million in 2026.
• Business Quant data shows FATE's Revenue at $1.3 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.